Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dynavax Technologies Corporation    DVAX

DYNAVAX TECHNOLOGIES CORPORATION

(DVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

India says local COVID-19 vaccine final trials could end within two months

11/22/2020 | 12:09pm EST

NEW DELHI, Nov 22 (Reuters) - India's health minister said on Sunday a locally-developed COVID-19 vaccine candidate could complete its final trials in a month or two, raising hopes for a rapid roll-out in a country with the world's second highest number of infections.

The state-run Indian Council of Medical Research (ICMR) and privately-held Bharat Biotech this month started third-stage trials of COVAXIN, in a process that would involve 26,000 volunteers. It is the most advanced Indian experimental vaccine.

"We are in the process of developing our indigenous vaccines, in the process of completing our third-phase trials in the next one or two months," Harsh Vardhan told a web conference on the pandemic.

He reiterated the government's plan was to immunise 200 million to 250 million Indians by July.

An ICMR scientist told Reuters earlier this month the vaccine could be launched in February or March, although Bharat Biotech separately told Reuters on Friday that results of the late-stage trials were expected only between March and April.

Vardhan, however, said in September the government could opt for emergency vaccine authorisation, particularly for the elderly and people in high-risk workplaces.

Indian officials have said they expect to rely on COVAXIN and four other locally-tested candidates to control COVID-19, as they do not expect early access to sufficient quantities of those developed by Pfizer and Moderna.

The other experimental vaccines on trial in India are the one being developed by AstraZeneca and Oxford University that is being manufactured by the Serum Institute of India; Russia's Sputnik-V; Zydus Cadila's ZyCoV-D and lastly one that Biological E. Ltd is developing with Baylor College of Medicine and Dynavax Technologies Corp.

Serum's CEO said on Friday the AstraZeneca vaccine could be delivered to Indian healthcare workers and the elderly by January.

India on Sunday recorded 45,209 new infections, taking the total to 9.09 million, only behind that of the United States. Deaths rose by 501 to 133,227, with Delhi recording the highest number of daily fatalities in the country over the last few days. (Reporting by Krishna N. Das and Neha Arora; editing by Barbara Lewis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
CADILA HEALTHCARE LIMITED -1.92% 460.5 Delayed Quote.-3.41%
DYNAVAX TECHNOLOGIES CORPORATION 3.57% 5.22 Delayed Quote.17.30%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about DYNAVAX TECHNOLOGIES CORPORATION
01/21DYNAVAX TECHNOLOGIES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/20DYNAVAX TECHNOLOGIES : Names Kelly MacDonald as CFO, Succeeding Michael Ostrach
MT
01/12DYNAVAX TECHNOLOGIES CORP : Change in Directors or Principal Officers, Financial..
AQ
01/07DYNAVAX TECHNOLOGIES CORP : Other Events (form 8-K)
AQ
01/07DYNAVAX TECHNOLOGIES : Reports Positive Data From Study of New Four-Dose Regimen..
MT
2020Health group CEPI to help fund Indian drugmaker's COVID-19 vaccine
RE
2020DYNAVAX TECHNOLOGIES : Serum Institute of India Start Dosing in Early-Stage Tria..
MT
2020INDIA'S BIOLOGICAL E. TO START VACCI : executive
RE
2020India readies for 600 mln COVID vaccine jabs; to use standard cold storage - ..
RE
2020India readies for 600 mln COVID vaccine jabs; to use standard cold storage - ..
RE
More news
Financials (USD)
Sales 2020 40,1 M - -
Net income 2020 -87,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,07x
Yield 2020 -
Capitalization 575 M 575 M -
Capi. / Sales 2020 14,4x
Capi. / Sales 2021 4,62x
Nbr of Employees 231
Free-Float 99,2%
Chart DYNAVAX TECHNOLOGIES CORPORATION
Duration : Period :
Dynavax Technologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYNAVAX TECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 16,00 $
Last Close Price 5,22 $
Spread / Highest target 283%
Spread / Average Target 207%
Spread / Lowest Target 168%
EPS Revisions
Managers and Directors
NameTitle
Ryan Spencer Chief Executive Officer & Director
David F. Novack President & Chief Operating Officer
Andrew A. F. Hack Chairman
Michael S. Ostrach Senior VP, Chief Financial & Business Officer
Robert Janssen Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
DYNAVAX TECHNOLOGIES CORPORATION17.30%575
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148